Table 2 Baseline characteristics of the target patient population
Characteristics | Intervention clinics at baseline (N = 1431) | Comparison clinics at baseline (N = 1717) | p value* |
|---|---|---|---|
Women, % (SD) | 57.7 (7.1) | 60.7 (8.9) | 0.400 |
Mean age, years, mean (SD) | 53.6 (3.2) | 53.8 (3.5) | 0.864 |
Completed treatment agreement (past 12 months), % (SD) | 24.8 (13.8) | 29.2 (18.3) | 0.531 |
Completed urine drug testing (past 12 months), % (SD) | 24.7 (11.8) | 31.3 (16.2) | 0.285 |
Completed depression screening (past 12 months), % (SD) | 8.1 (10.4) | 1.1 (1.3) | 0.019 |
Completed opioid misuse risk assessment, % (SD) | 0.2 (0.4) | 0.7 (1.8) | 0.478 |
Documented PDMP Check (past 12 months), % (SD) | 0.0 (0.1) | 0.3 (1.2) | 0.503 |
Co-prescribed benzodiazepines in at least 1 out of 3 past months, % (SD) | 19.9 (4.3) | 24.7 (7.4) | 0.089 |
Percentage of the adult clinic population, % (SD) | 2.0 (0.9) | 2.1 (0.6) | 0.906 |
MED (past 90 days), mg/day, mean (SD) | 75.7 (29.7) | 55.9 (19.4) | 0.063 |
MED ≥ 90 mg/day (past 90 days), % (SD) | 23.0 (8.8) | 15.5 (7.3) | 0.038 |